Change in Serum Lactate Dehydrogenase Is Associated with Outcome of Patients with Advanced-stage NSCLC Treated with Erlotinib
Language English Country Greece Media print
Document type Journal Article
PubMed
27127158
PII: 36/5/2459
Knihovny.cz E-resources
- Keywords
- EGFR-TKI, LDH, Lactate dehydrogenase, NSCLC, biomarker, erlotinib, lung cancer, prediction,
- MeSH
- Adult MeSH
- Erlotinib Hydrochloride therapeutic use MeSH
- L-Lactate Dehydrogenase blood MeSH
- Middle Aged MeSH
- Humans MeSH
- Lung Neoplasms blood drug therapy MeSH
- Carcinoma, Non-Small-Cell Lung blood drug therapy MeSH
- Antineoplastic Agents therapeutic use MeSH
- Retrospective Studies MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Treatment Outcome MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- Erlotinib Hydrochloride MeSH
- L-Lactate Dehydrogenase MeSH
- Antineoplastic Agents MeSH
BACKGROUND: Serum lactate dehydrogenase (LDH) has been reported as a prognostic biomarker in malignant diseases. However, little is known on the dynamics of serum LDH levels during systemic treatment. We focused on the association of changes in serum LDH with outcome of patients with advanced-stage non-small cell lung cancer (NSCLC) treated with erlotinib. PATIENTS AND METHODS: Clinical data of 309 patients were analyzed. Serum samples were collected within one week before initiation and after one month of treatment. RESULTS: The change in serum LDH during the first month of erlotinib treatment was independently associated with disease control rate (p=0.006), progression-free survival (PFS) (p=0.010) and overall survival (OS) (p<0.001). CONCLUSION: LDH is a commonly used serum biomarker, that is cheap and easy to detect. The results of our study suggest that the change in LDH serum level during the first month is a surrogate marker on the efficacy of erlotinib in patients with advanced NSCLC.
Center for Applied Genomics of Solid Tumours Genomac Research Institute Prague Czech Republic
Institute of Biostatistics and Analysis Faculty of Medicine Masaryk University Brno Czech Republic
